OTCM
CNVVF
Market cap6.02bUSD
Oct 20, Last price
3.32
Name
ConvaTec Group PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ConvaTec Group Plc is a global medical technology company focused on creating, producing, and distributing a wide array of healthcare products. Their offerings span several key areas: Advanced Wound Management: This includes specialized dressings and skincare solutions for treating both acute and chronic wounds, which can arise from conditions like diabetes, prolonged immobility, venous disease, traumatic injuries, burns, or surgical interventions. Ostomy Care: The company provides vital devices, accessories, and support services for individuals who have undergone ostomy procedures, often necessitated by conditions such as colorectal or bladder cancer, inflammatory bowel disease, or obesity. Continence and Critical Care: This division offers intermittent urinary catheters and related products to help manage urinary continence issues for patients with spinal cord injuries, multiple sclerosis, spina bifida, and other urological conditions. It also supplies a range of devices crucial for intensive care units and broader hospital settings. Specialized Monitoring and Management Systems: ConvaTec develops advanced systems for managing acute fecal incontinence, meticulously monitoring urine output, and assessing intra-abdominal pressure. Disposable Medical Supplies: Their portfolio includes a variety of single-use medical items such as wound drainage systems, urine collection bags and catheters, equipment for airway management and oxygen therapy, suction apparatus, gastroenterology tubes, and securement devices. Infusion Technology: They also manufacture disposable infusion sets for insulin pumps used in diabetes care, as well as for other continuous infusion treatments. ConvaTec distributes its products globally to a diverse clientele, including pharmacies, hospitals, and various acute and post-acute healthcare providers, either directly or via a network of distributors and wholesalers. Their customer base encompasses healthcare professionals, patients, and other manufacturers. Founded in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
Related entities
Subsidiaries (6)
180 MEDICAL, INC.
CONVATEC HEALTHCARE D S.ÀR.L.
CONVATEC HOLDINGS U.K. LIMITED
CONVATEC INC.
CONVATEC INTERNATIONAL SERVICES GMBH
UNOMEDICAL A/S
Key people
Non-Executive Independent Chairman of the Board · since 2019
Chief Executive Officer, Executive Director · since 2019
Jonny Mason
Chief Financial Officer, Executive Director · since 2022
Fiona Ryder
Interim Chief Financial Officer · since 2025
Anne Belcher
President and Chief Operating Officer - Global Emerging Markets · since 2022
President and Chief Operating Officer - Infusion Care · since 2021
Mark Jassey
President and Chief Operating Officer - Continence Care and Home Services Group · since 2024
Bruno Pinheiro
President and Chief Operating Officer - Ostomy Care · since 2022
David Shepherda
President and Chief Operating Officer - Advanced Wound Care · since 2019
John Haller
Executive Vice President, Chief Quality and Operations Officer · since 2022
Evelyn Douglas
Executive Vice President, Chief Strategy and Business Development Officer · since 2023
James Kerton
Executive Vice President, General Counsel, Company Secretary · since 2024
Divakar Ramakrishnan
Executive Vice President, Chief Technology Officer and Head - Research and Development · since 2022
Emma Rosei
Chief Human Resources Officer, Executive Vice President · since 2024
Senior Non-Executive Independent Director · since 2019
Constantin Freng
Non-Executive Independent Director · since 2020
Kimberly Lody
Non-Executive Independent Director · since 2022
Non-Executive Independent Director · since 2020
Non-Executive Independent Director · since 2022
Headquarters & legal address
7TH FLOOR
20 EASTBOURNE TERRACE
LONDON, LND W2 6LG
GB
20 EASTBOURNE TERRACE
LONDON, LND W2 6LG
GB
Previous name
CONVATEC GROUP LIMITED
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||